RECURRENT CANCER

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This study is testing a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has returned or not responded to treatment. The goal is to see if the combination can stop the cancer from growing for at least 6 mon…

This study tests a new type of radiation called spatially fractionated radiation therapy for people with cervical cancer or pelvic cancer that has come back. It is for patients who cannot get the usual brachytherapy because of unusual anatomy or large tumors. The goal is to see i…

This trial tests whether giving children and teens with advanced solid tumors, brain tumors, or lymphomas drugs that match their tumor's genetic profile can help. About 90 participants will receive one of four drug combinations based on their tumor's molecular features. The goal …

This study tests a drug called cabozantinib in 20 adults whose liver cancer returned after a liver transplant. The goal is to see if the drug can control the cancer. Participants take the drug until it stops working or side effects become too bothersome.